NASDAQ:SILO Silo Pharma Q3 2025 Earnings Results & Report $1.25 +0.03 (+2.05%) As of 02:53 PM Eastern This is a fair market value price provided by Massive. Learn more. Silo Pharma reported Q3 2025 earnings on November 13, 2025. The company reported EPS of -$1.80, while revenue was $0.02 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 13, 2025TimeAfter Market Closes Silo Pharma EPS ResultsActual EPS-$1.80Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ASilo Pharma Revenue ResultsActual Revenue$0.02 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsSilo Pharma's next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Silo Pharma Q3 2025 Earnings FAQ Did Silo Pharma beat earnings estimates for Q3 2025? Silo Pharma (NASDAQ:SILO) reported earnings of -$1.80 per share for Q3 2025. The report was announced on Thursday, November 13, 2025. What was Silo Pharma's revenue for Q3 2025? Silo Pharma reported revenue of $0.02 million for Q3 2025. When is Silo Pharma's next earnings date? Silo Pharma's next earnings date is estimated for Wednesday, December 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for Silo Pharma on the company's earnings history page. Silo Pharma Earnings HeadlinesSilo Pharma’s QwikAgents Expands AI Agent Platform with NVIDIA Model Support and New Runtime FlexibilitySeptember 30, 2026 | markets.businessinsider.comSilo Pharma's QwikAgents Expands AI Agent Platform with NVIDIA Model Support and New Runtime FlexibilitySeptember 30, 2026 | globenewswire.comDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.October 14 at 1:00 AM | Porter & Company (Ad)Silo Pharma Gets U.S. Patent Allowance For SPC-15 PTSD TreatmentSeptember 18, 2026 | rttnews.comSilo Pharma Receives U.S. Patent Allowance For SPC-15 Ptsd TreatmentSeptember 18, 2026 | marketscreener.comMSilo Pharma Receives USPTO Notice of Allowance for SPC-15 Patent Covering Stress-Induced Behavioral Response PreventionSeptember 18, 2026 | quiverquant.comQSee More Silo Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Silo Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Silo Pharma and other key companies, straight to your email. Email Address About Silo PharmaSilo Pharma (NASDAQ:SILO) is a development-stage biopharmaceutical company focused on creating novel therapies for conditions involving the central nervous system, pain, inflammation and mental health. The company combines established pharmaceutical compounds, including ketamine and psychedelic-related compounds, with proprietary drug-delivery technologies intended to improve treatment administration and patient outcomes. Silo’s development programs have included SP-26, an implant-based ketamine therapy being investigated for fibromyalgia, as well as other potential treatments involving intranasal, transdermal and implant delivery systems. The company has also pursued programs addressing post-traumatic stress disorder, rheumatoid arthritis, Alzheimer’s disease and other neurological or inflammatory conditions. Its products remain in development and are subject to regulatory review and clinical testing. Headquartered in Englewood Cliffs, New Jersey, Silo Pharma has worked with academic and research institutions to advance its pipeline and secure rights to certain technologies and compounds. The company is led by Chief Executive Officer Eric Weisblum. Its operations and potential commercial reach are primarily tied to the development and future regulatory approval of its investigational therapies.View Silo Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
